Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by E. Orava
P2.15-09 the Impact of Treatment Evolution in NSCLC (iTEN) Model: Survival and Cost of Treating Patients With Advanced NSCLC in 2017
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA18.02 the Impact of Treatment Evolution in NSCLC (iTEN) Model: Development and Validation
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
P2.15-16 Clinical Economic Impact of Improved Genotyping in Patients With Advanced Non-Small Cell Lung Adenocarcinoma (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Pcn86 - Validation of the Impact of Treatment Evolution in Non-Small Cell Lung Cancer (Nsclc) Model (Iten): A Discrete Event Patient Simulation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
P2.15-18 Cost-Effectiveness Analysis of Second-Line Immune Checkpoint Inhibitors for Advanced NSCLC in Colombia
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.17-09 Retrospective Analysis of the Efficacy and Safety of Multimodal Treatment for Locally-Advanced NSCLC in Elderly Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-09 Impact of Urban or Rural Residence on Overall Survival for Patients With Metastatic Non-Squamous NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.15-31 the Evolution of Costs in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada Between 1999 to 2014
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-04 Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib
Lung Cancer Management